Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
Provided By GlobeNewswire
Last update: Jan 13, 2025
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –
Read more at globenewswire.com1.28
+0.06 (+4.92%)
Find more stocks in the Stock Screener
HOWL Latest News and Analysis
9 days ago - ChartmillTop movers in Tuesday's after hours sessionAs the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
